Open Access

Juan Muñoz-Moreno, José Añorga-Ocmin, Sandra Espinola-García, Cristian Aguilar-Carranza, Walter Alarco-León

2020.6.29Archivos Peruanos de Cardiologia y Cirugia Cardiovascular

DOI: 10.47487/apcyccv.v1i2.40

tlooto Summary

En este estudio sobre amiloidosis cardíaca en un centro especializado las manifestaciones cli⩽nicas más frecuentes fueron la insuficiencia cardi y the neuropatía sensitivo-motora, y en todos los casos como muerte súbita.

Abstract

Objectives To determine the clinical, imaging and laboratory characteristics and one year after diagnosis survival of patients with cardiac amyloidosis in a national reference hospital.

Materials and methods Case series study. We evaluated the clinical characteristics, complementary examinations and survival of patients with cardiac amyloidosis diagnosed, treated and followed up in the Clinical Cardiology service of the National Cardiovascular Institute - INCOR EsSalud in Lima, Peru.

Results We found eight patients with diagnosis of cardiac amyloidosis. The median age was 64.5 years and 75% were male. The etiology of cases was unspecified cardiac amyloidosis (25%), transthyretin cardiac amyloidosis (37.5%), and light chain cardiac amyloidosis (37.5%). Symptomatic heart failure (NYHA II-III) was the most common initial presentation symptom (87.5%). The most frequent extracardiac manifestations were: sensory-motor neuropathy (62.5%), musculoskeletal (37.5%), nephropathy (25%), bilateral carpal tunnel syndrome (25%), monoclonal gammopathies (25%) and refractory pleural effusion (25 %). Survival at one year was 75% and the cause of the 2 deaths was sudden death.

Conclusions In this study of cardiac amyloidosis at a specialized center, the most frequent clinical manifestations were heart failure and sensory-motor neuropathy. Mortality was 25% per year, and in all cases as sudden death.

Citation format

MUÑOZ-MORENO, Juan, et al. Amiloidosis cardíaca: Experiencia en un instituto cardiovascular de referencia nacional. Archivos Peruanos de Cardiologia y Cirugia Cardiovascular, 2020, 1: 75–84.